Navigation Links
Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
Date:4/14/2008

SAN DIEGO and SUNNYVALE, Calif., April 14 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today presented results from its preclinical program evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in B-cell receptor (BCR) modulated diseases such as lymphomas and autoimmune diseases. The data were presented during the Annual Meeting of the American Association for Cancer Research (AACR) being held this week in San Diego, CA.

Researchers conducted studies with PCI-32765 examining the downstream signaling events in the BCR signal transduction pathways. In vitro drug treatment of B-cell lymphomas blocked BCR mediated signaling and in vivo drug treatment of lymphoma-bearing animal models resulted in inhibition of tumor growth. Normal human B-cell activation was also shown to be inhibited by drug treatment in vitro. PCI-32765 also showed significant activity in animal models of arthritis.

"These studies highlight the importance of Btk in immune mediated diseases," said Joseph J. Buggy, Ph.D., vice president of research for Pharmacyclics. "Further, these data support our ongoing IND-enabling studies for PCI-32765, and our plans for an anticipated clinical trial later this year."

B-cells are a type of white blood cell that normally play a key role in the body's immune response. However, when B-cells are overactive, the immune system produces inflammatory cells and antibodies that begin to attack the body's own tissue, leading to autoimmune diseases such as rheumatoid arthritis. Most lymphomas are caused by uncontrolled growth of B-cells. Btk is an enzyme that plays a crucial role in B-cell activation and inhibition of its function may be useful in the treatment of imm
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
3. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
4. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
5. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
6. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
7. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
11. Favrille Announces Data Cutoff for Phase 3 Registration Trial of Specifid; Data Analysis and Unblinding Expected in June
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- Wrightington, Wigan and Leigh NHS ... ) are delighted to announce WWL,s decision to implement ... system. The system will be implemented across all three ... delivers healthcare in the future. WWL ... and on-budget system implementations as well as its proven ...
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Decision Resources ... devices in Brazil , ... China (BRIC) will see robust ... are increasingly favored over surgical procedures. Although revenues will ... resources, reimbursement challenges, prolonged device approval times and demand ...
Breaking Medicine Technology:Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3
... Australia, Sept. 26 Hospira, Inc. (NYSE: ... injectable pharmaceuticals, today announced that it has received ... biosimilar filgrastim product, Nivestim™. Nivestim ... including the prevention of febrile neutropenia (FN) and ...
... Pharma US, Inc. ("Astellas") announced results of a ... comparable to placebo in causing a >15% decrease ... in subjects with asthma or chronic obstructive pulmonary ... perfusion imaging (MPI) studies(1). Results were presented during ...
Cached Medicine Technology:Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 2Hospira Receives TGA Approval for Nivestim™, Australia's First Biosimilar Filgrastim 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 2Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 3Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 4Lexiscan® (Regadenoson) Injection Study in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD) Presented as Late-Breaker at American Society of Nuclear Cardiology 2010 5
(Date:9/30/2014)... By Dennis Thompson ... -- The first confirmed case of Ebola has surfaced in ... from Liberia, federal health officials announced late Tuesday. The ... Hospital in Dallas, has been diagnosed with the deadly ... Prevention said in a late afternoon news conference. The ...
(Date:9/30/2014)... Health Day Reporter TUESDAY, ... who are overweight or obese when diagnosed appear to ... weight-related cancer, new research suggests. , , The finding ... only the potential for developing other cancers associated with ... who reported being overweight or obese prior to diagnosis ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling costs ... treat Medicare patients has had no meaningful impact on ... in the Journal of Clinical Oncology published ... chemotherapy to treat colorectal and lung cancers, and did ... those drugs following the implementation of the recent Medicare ...
(Date:9/30/2014)... 30, 2014 Research by UC Irvine immunologists reveals ... light on a vital process that determines how the ... online version of Nature Immunology , neurology professor ... Institute for Immunology colleagues describe a critical mechanism underlying ... the bloodstream. , A T cell is a type ...
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Fat ... nutrition specialist and best-selling author Mike Geary that is helping ... transform their body into a fat-burning machine in less than ... an investigative review. , “In our culture that is ... be hard to decipher what is really fact and fiction ...
Breaking Medicine News(10 mins):Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:UCI study uncovers important process for immune system development 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3
... diseases and treatments, experts say , FRIDAY, Oct. 16 ... map of the human epigenome, gaining greater understanding of ... we,ve been limited to viewing small snippets of the ... Analysis Laboratory at the Salk Institute for Biological Studies ...
... 16 When Royal Caribbean International officially names Oasis ... revolutionary cruise ship - on Nov. 30, 2009 from Port ... line will be doing more than making wishes come true ... the country through the Make-A-Wish Foundation. Royal Caribbean will be ...
... increasing the overall death rate in the German population. Matthias ... Sciences of the University of Hamburg and his co-authors present ... Deutsches rtzeblatt International ( Dtsch Artzebl Int 2009; ... index (BMI) between 25 and 29.9 kg/m2. About 20% are ...
... ... the nation,s first association for providers of private pay home care, has announced that a state ... ... association for providers of private pay home care, has announced that a state chapter has been ...
... work can stave off disease and decline, study finds, ... to a healthier retirement may be surprising: work. , ... part-time, are less likely to experience physical decline and ... the national Health and Retirement Study, researchers analyzed six ...
... Deborah Friberg, Chief Operating Officer and Executive Vice ... has been named the recipient of the first annual ... presented by the Association for Professionals in Infection Control ... executive team member who has demonstrated significant support for ...
Cached Medicine News:Health News:Scientists Provide First Map of Complete Human Epigenome 2Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 2Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 3Health News:Royal Caribbean to Grant Wishes Onboard Oasis Of The Seas 4Health News:National Private Duty Association Announces Formation of an Iowa Chapter 2Health News:For a Healthier Retirement, Work a Little 2Health News:For a Healthier Retirement, Work a Little 3Health News:APIC Announces Winner of First Healthcare Administrator Award 2Health News:APIC Announces Winner of First Healthcare Administrator Award 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: